Cargando…

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer

PURPOSE: The effects of immune checkpoint inhibitors have been reported to be linked with immune-related adverse events (irAEs). In patients with advanced non-small-cell lung cancer, who tested positive for programmed death-ligand 1 (PD-L1), pembrolizumab, an immune checkpoint inhibitor can be used...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noguchi, Susumu, Suminaga, Keiichiro, Kaki, Takahiro, Kawachi, Hiroaki, Fukao, Akari, Terashita, Satoshi, Horikawa, Sadao, Ikeue, Tatsuyoshi, Sugita, Takakazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367935/ https://www.ncbi.nlm.nih.gov/pubmed/32765147 http://dx.doi.org/10.2147/LCTT.S254146

Ejemplares similares

Visceral pleural biopsy under medical thoracoscopy for the diagnosis of lung adenocarcinoma
por: Terashita, Satoshi, et al.
Publicado: (2020)

Sarcoid-Like Granulomatosis Induced by Nivolumab Treatment in a Lung Cancer Patient
por: Noguchi, Susumu, et al.
Publicado: (2018)

Osimertinib Administration as the Primary Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy for Brain Metastasis of De Novo T790M-positive Lung Cancer
por: Noguchi, Susumu, et al.
Publicado: (2019)

Endobronchial Manifestation of Methotrexate-induced Lymphoproliferative Disorder
por: Ikeue, Tatsuyoshi, et al.
Publicado: (2019)

Pleuritis Caused by Mycobacterium kyorinense without Pulmonary Involvement
por: Ikeue, Tatsuyoshi, et al.
Publicado: (2017)

Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy
por: Terashita, Satoshi, et al.
Publicado: (2019)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

Metachronous immune-related adverse events involving type 1 diabetes and isolated adrenocorticotropic hormone deficiency associated with pembrolizumab monotherapy for metastatic head and neck cancer: a case report
por: Iijima, Hiroaki, et al.
Publicado: (2023)

Pembrolizumab‐caused polyradiculoneuropathy as an immune‐related adverse event
por: Kurashige, Takashi, et al.
Publicado: (2021)

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
por: Almutairi, Abdulaali R., et al.
Publicado: (2020)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab
por: Lima, Gian, et al.
Publicado: (2019)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
por: Isono, Taisuke, et al.
Publicado: (2021)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
por: de Filette, Jeroen, et al.
Publicado: (2016)

Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients
por: Schaefer, Anne, et al.
Publicado: (2020)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
por: Nishio, Shin, et al.
Publicado: (2020)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
por: Gohara, Kazuki, et al.
Publicado: (2021)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer
por: Kasajima, Masashi, et al.
Publicado: (2023)

Durable response after the discontinuation of pembrolizumab treatment due to an adverse event in a patient with advanced endometrial cancer: A case report
por: Umihira, Shuntaro, et al.
Publicado: (2022)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus
por: Jono, Misato, et al.
Publicado: (2019)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
por: Shah, N., et al.
Publicado: (2019)

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
por: Eun, Yeonghee, et al.
Publicado: (2019)

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
por: Terai, Hideki, et al.
Publicado: (2022)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
por: Kawachi, Hayato, et al.
Publicado: (2023)

Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus
por: Takemura, Masao, et al.
Publicado: (2021)

Analyses of non-benzodiazepine-induced adverse events and prognosis in elderly patients based on the Japanese adverse drug event report database
por: Noguchi, Yoshihiro, et al.
Publicado: (2018)

IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis
por: Mitarai, Yuki, et al.
Publicado: (2021)

Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports
por: Thomsen, Kenneth, et al.
Publicado: (2018)

Adverse Endocrine-Related Effects of Pembrolizumab Precipitating Severe Hyponatremia
por: Baldawi, Muaamar B, et al.
Publicado: (2022)

A large-scale survey of adverse events experienced in yoga classes
por: Matsushita, Tomoko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_40c7ffqbiu24g1mct5q8ug24bt